Fulgent Genetics, Inc. Stock

Equities

FLGT

US3596641098

Healthcare Facilities & Services

Market Closed - Nasdaq 04:00:00 2024-04-19 pm EDT 5-day change 1st Jan Change
20.36 USD +1.24% Intraday chart for Fulgent Genetics, Inc. -2.02% -29.57%
Sales 2024 * 279M Sales 2025 * 322M Capitalization 601M
Net income 2024 * -69M Net income 2025 * -58M EV / Sales 2024 * -0.71 x
Net cash position 2024 * 800M Net cash position 2025 * 755M EV / Sales 2025 * -0.48 x
P/E ratio 2024 *
-8.71 x
P/E ratio 2025 *
-10.7 x
Employees 1,184
Yield 2024 *
-
Yield 2025 *
-
Free-Float 61.71%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.10%
1 week-4.56%
Current month-7.33%
1 month-7.46%
3 months-23.01%
6 months-20.17%
Current year-30.44%
More quotes
1 week
19.88
Extreme 19.88
20.96
1 month
19.88
Extreme 19.88
22.23
Current year
19.88
Extreme 19.88
29.91
1 year
19.88
Extreme 19.88
44.09
3 years
19.88
Extreme 19.88
112.00
5 years
4.71
Extreme 4.712
189.89
10 years
2.73
Extreme 2.725
189.89
More quotes
Managers TitleAgeSince
Chief Executive Officer 68 16-05-12
Founder 58 16-05-12
Director of Finance/CFO 56 15-12-31
Members of the board TitleAgeSince
Chief Executive Officer 68 16-05-12
Director/Board Member 74 19-07-31
Director/Board Member 66 23-01-02
More insiders
Date Price Change Volume
24-04-19 20.36 +1.24% 156 226
24-04-18 20.11 +0.10% 219,603
24-04-17 20.09 -3.04% 221,621
24-04-16 20.72 -0.14% 157,558
24-04-15 20.75 -0.14% 190,824

Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT

More quotes
Fulgent Genetics, Inc. is a technology-based genetic company with a laboratory services business and a therapeutic development business. The Company’s laboratory services business includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile (PK) profile of new and existing cancer drugs. Its technology platform for its laboratory services business includes gene probes, data suppression and comparison algorithms, learning software, and laboratory information management systems. The platform provides a test menu, the ability to rapidly develop and launch new tests and customizable test offerings. The Company also offers next-generation sequencing (NGS) services.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
20.11 USD
Average target price
26.67 USD
Spread / Average Target
+32.60%
Consensus